News | Contrast Media | February 07, 2018

ACR Introduces New Contrast Reaction Card

Companion to ACR Manual on Contrast Media meant to help improve management of contrast-related adverse events

ACR Introduces New Contrast Reaction Card

February 7, 2018 — The American College of Radiology (ACR) introduced a new contrast reaction card that summarizes important steps to be taken when managing an acute reaction to contrast material.

Offered as an addition to the ACR Manual on Contrast Media, the card outlines multiple common and serious contrast reactions. The free resource also includes details on premedication and extravasations.

"Managing contrast reactions is a necessary, important and stressful part of a radiologist's job. In the heat of the moment it can be difficult to remember critical details like the dose of epinephrine. This card can help improve that process,” said Matthew Davenport, M.D., chair of the American College of Radiology Committee on Drugs and Contrast Media.

The card is about the size of a driver's license. To use in your practice simply:

  • Print the cards;
  • Enter the phone number your health system uses to activate a "CODE BLUE"; and
  • Distribute the cards.

“Of course, no reference card can be a substitute for the sound judgment and expertise of a licensed physician. However, we hope these cards will be a valuable asset in any radiology practice,” said Davenport.

The Contrast Reaction Card is now available for download in both Landscape and Portrait formats.

For more information: www.acr.org

 

Related Content

Guerbet Partners With Imalogix on Dose Optimization With Artificial Intelligence
News | Radiation Dose Management | August 14, 2018
August 14, 2018 — Guerbet LLC USA announced a commercial partnership with Imalogix, a provider of...
Videos | Contrast Media | August 03, 2018
Lawrence Tanenbaum, M.D., FACR, vice president and director of advanced imaging at RadNet, discusses the latest resea
Guerbet, IBM Watson Health Partner on Artificial Intelligence for Liver Imaging
News | Clinical Decision Support | July 10, 2018
Guerbet announced it has signed an exclusive joint development agreement with IBM Watson Health to develop an...
Imaging agent helps predict success of lung cancer therapy
News | Oncology Diagnostics | March 08, 2018
March 8, 2018 – Doctors contemplating the best therapy for...
OptiStar Elite injector
Feature | Contrast Media Injectors | March 07, 2018 | Grand View Research Inc.
The global contrast media injectors market is expected to reach $1.4 billion by 2025, growing at a compound annual...
TriHealth in Cincinnati

TriHealth in Cincinnati.

Sponsored Content | Case Study | Contrast Media Injectors | March 06, 2018
The continuing search for advantages to improve workflow has radiology departments constantly searching for new...
Guerbet Presents Contrast&Care Injection Management Solution at ECR 2018
News | Contrast Media | February 28, 2018
February 28, 2018 — Guerbet will present its new Contrast&Care application, as well as other...
A brain MRI. Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns. Gadolinium deposition in the brain has raised concerns about Gadolinium toxicity.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Feature | Magnetic Resonance Imaging (MRI) | February 16, 2018 | Dave Fornell
One of the biggest concerns in radiology in recent years is the safety of gadolinium-based contrast agents (GBCAs) us
Bracco Diagnostics' MultiHance Contrast Agent Earns Expanded Approval for Pediatric MRI
News | Contrast Media | January 30, 2018
Bracco Diagnostics Inc. announced the labeling of its contrast agent MultiHance has obtained U.S. Food and Drug...
Overlay Init